

Patrice Dubreuil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7733930/publications.pdf>

Version: 2024-02-01

161
papers

9,909
citations

20817

60
h-index

39675

94
g-index

166
all docs

166
docs citations

166
times ranked

9328
citing authors

#	ARTICLE	IF	CITATIONS
1	Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. <i>Nature</i> , 1994, 368, 643-648.	27.8	423
2	Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT. <i>PLoS ONE</i> , 2009, 4, e7258.	2.5	346
3	Pediatric Mastocytosis Is a Clonal Disease Associated with D816V and Other Activating c-KIT Mutations. <i>Journal of Investigative Dermatology</i> , 2010, 130, 804-815.	0.7	329
4	Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors. <i>Cancer Research</i> , 2013, 73, 3499-3510.	0.9	277
5	Nectin4/PRR4, a New Afadin-associated Member of the Nectin Family That Trans-interacts with Nectin1/PRR1 through V Domain Interaction. <i>Journal of Biological Chemistry</i> , 2001, 276, 43205-43215.	3.4	263
6	Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors. <i>Journal of Veterinary Internal Medicine</i> , 2008, 22, 1301-1309.	1.6	244
7	DNAM-1 and PVR Regulate Monocyte Migration through Endothelial Junctions. <i>Journal of Experimental Medicine</i> , 2004, 199, 1331-1341.	8.5	236
8	KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. <i>Leukemia</i> , 2015, 29, 1223-1232.	7.2	229
9	Lineage-specific enhancers activate self-renewal genes in macrophages and embryonic stem cells. <i>Science</i> , 2016, 351, aad5510.	12.6	194
10	Socs1 binds to multiple signalling proteins and suppresses Steel factor-dependent proliferation. <i>EMBO Journal</i> , 1999, 18, 904-915.	7.8	192
11	The human PRR2 gene, related to the human poliovirus receptor gene (PVR), is the true homolog of the murine MPH gene. <i>Gene</i> , 1995, 159, 267-272.	2.2	179
12	Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. <i>Oncogene</i> , 2003, 22, 660-664.	5.9	179
13	The Human Poliovirus Receptor Related 2 Protein Is a New Hematopoietic/Endothelial Homophilic Adhesion Molecule. <i>Blood</i> , 1998, 92, 4602-4611.	1.4	159
14	Complementary DNA characterization and chromosomal localization of a human gene related to the poliovirus receptor-encoding gene. <i>Gene</i> , 1995, 155, 261-265.	2.2	156
15	Mast cell leukemia. <i>Blood</i> , 2013, 121, 1285-1295.	1.4	153
16	Gain-of-Function Mutations in the Extracellular Domain of KIT Are Common in Canine Mast Cell Tumors. <i>Molecular Cancer Research</i> , 2008, 6, 1137-1145.	3.4	147
17	Paediatric mastocytosis: a systematic review of 1747 cases. <i>British Journal of Dermatology</i> , 2015, 172, 642-651.	1.5	143
18	Nectin-4, a New Serological Breast Cancer Marker, Is a Substrate for Tumor Necrosis Factor- α -converting Enzyme (TACE)/ADAM-17. <i>Journal of Biological Chemistry</i> , 2005, 280, 19543-19550.	3.4	136

#	ARTICLE	IF	CITATIONS
19	Systemic mastocytosis and bone involvement in a cohort of 75 patients. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1838-1841.	0.9	135
20	Case-Control Cohort Study of Patients' Perceptions of Disability in Mastocytosis. <i>PLoS ONE</i> , 2008, 3, e2266.	2.5	135
21	Nectin-4 is a new histological and serological tumor associated marker for breast cancer. <i>BMC Cancer</i> , 2007, 7, 73.	2.6	134
22	Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 5-14.	1.7	133
23	Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 16.	6.2	128
24	Nectin2 [±] (PRR2 [±] or HveB) and Nectin2 ⁺ Are Low-Efficiency Mediators for Entry of Herpes Simplex Virus Mutants Carrying the Leu25Pro Substitution in Glycoprotein D. <i>Journal of Virology</i> , 2000, 74, 1267-1274.	3.4	126
25	The tumor suppressor activity of SOCS-1. <i>Oncogene</i> , 2002, 21, 4351-4362.	5.9	123
26	The V domain of herpesvirus Ig-like receptor (HlgR) contains a major functional region in herpes simplex virus-1 entry into cells and interacts physically with the viral glycoprotein D. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 15700-15705.	7.1	117
27	Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. <i>Blood</i> , 2015, 126, 1009-1016.	1.4	116
28	Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. <i>Journal of Neuroinflammation</i> , 2016, 13, 177.	7.2	116
29	Prominent Role of the Ig-like V Domain intrans-Interactions of Nectins. <i>Journal of Biological Chemistry</i> , 2002, 277, 27006-27013.	3.4	115
30	Cell-to-Cell Spread of Wild-Type Herpes Simplex Virus Type 1, but Not of Syncytial Strains, Is Mediated by the Immunoglobulin-Like Receptors That Mediate Virion Entry, Nectin1 (PRR1/HveC/HlgR) and Nectin2 (PRR2/HveB). <i>Journal of Virology</i> , 2000, 74, 3909-3917.	3.4	106
31	Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. <i>BMC Neurology</i> , 2012, 12, 36.	1.8	104
32	Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study. <i>American Journal of Hematology</i> , 2010, 85, 921-925.	4.1	98
33	Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. <i>Lancet, The</i> , 2017, 389, 612-620.	13.7	95
34	Expression and Signal Transduction of the FLT3 Tyrosine Kinase Receptor. <i>Acta Haematologica</i> , 1996, 95, 218-223.	1.4	90
35	In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. <i>Blood</i> , 2012, 120, 4846-4849.	1.4	89
36	Gastrointestinal involvement and manifestations in systemic mastocytosis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1247-1253.	1.9	88

#	ARTICLE	IF	CITATIONS
37	Phenotypic and Genotypic Characteristics of Mastocytosis According to the Age of Onset. PLoS ONE, 2008, 3, e1906.	2.5	84
38	Anti-CD2 (sheep red blood cell receptor) monoclonal antibodies and T cell activation I. Pairs of anti-T11.1 and T11.2 (CD2 subgroups) are strongly mitogenic for T cells in presence of 12-O-tetradecanoylphorbol 13-acetate. European Journal of Immunology, 1986, 16, 1063-1068.	2.9	81
39	Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. Journal of Experimental Medicine, 2005, 202, 1635-1641.	8.5	81
40	Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. Oncogene, 2007, 26, 298-307.	5.9	81
41	A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection. Blood, 2014, 124, 111-120.	1.4	80
42	A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Annals of Oncology, 2015, 26, 1194-1200.	1.2	78
43	Suppressor of Cytokine Signaling 6 Associates with KIT and Regulates KIT Receptor Signaling. Journal of Biological Chemistry, 2004, 279, 12249-12259.	3.4	71
44	Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling. European Journal of Medicinal Chemistry, 2012, 47, 239-254.	5.5	70
45	SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor. Leukemia, 1999, 13, 1374-1382.	7.2	69
46	Human nectin3/PRR3: a novel member of the PVR/PRR/nectin family that interacts with afadin. Gene, 2000, 255, 347-355.	2.2	68
47	Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS. JCI Insight, 2017, 2, .	5.0	68
48	The c-fms gene complements the mitogenic defect in mast cells derived from mutant W mice but not mi (microphthalmia) mice.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 2341-2345.	7.1	67
49	Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. American Journal of Veterinary Research, 2010, 71, 1354-1361.	0.6	67
50	Molecular Defects in Mastocytosis. Immunology and Allergy Clinics of North America, 2014, 34, 239-262.	1.9	67
51	DNMT3A R882H mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice. Leukemia, 2016, 30, 1388-1398.	7.2	67
52	Two distinct TL-like molecular subsets defined by monoclonal antibodies on the surface of human thymocytes with different expression on leukemia lines. Immunogenetics, 1984, 20, 253-264.	2.4	66
53	Gastrointestinal manifestations in mastocytosis: A study of 83 patients. Journal of Allergy and Clinical Immunology, 2013, 132, 866-873.e3.	2.9	66
54	Signal transduction by several KIT juxtamembrane domain mutations. Oncogene, 2003, 22, 4710-4722.	5.9	65

#	ARTICLE	IF	CITATIONS
55	ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases. <i>PLoS ONE</i> , 2014, 9, e95362.	2.5	65
56	Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial. <i>Annals of Oncology</i> , 2014, 25, 1762-1769.	1.2	65
57	Trisomy 4, a new chromosomal abnormality in Waldenström's macroglobulinemia: a study of 39 cases. <i>Leukemia</i> , 2006, 20, 1634-1636.	7.2	64
58	Mast cells' involvement in inflammation pathways linked to depression: evidence in mastocytosis. <i>Molecular Psychiatry</i> , 2016, 21, 1511-1516.	7.9	64
59	Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. <i>Blood</i> , 2006, 108, 1065-1072.	1.4	62
60	Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model. <i>PLoS ONE</i> , 2010, 5, e9430.	2.5	62
61	The murine homolog of human Nectin1delta serves as a species nonspecific mediator for entry of human and animal alpha herpesviruses in a pathway independent of a detectable binding to gD. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 4867-4872.	7.1	60
62	Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. <i>Arthritis Research and Therapy</i> , 2009, 11, R95.	3.5	60
63	Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. <i>Leukemia</i> , 2010, 24, 642-645.	7.2	58
64	Mechanisms of STAT Protein Activation by Oncogenic KIT Mutants in Neoplastic Mast Cells. <i>Journal of Biological Chemistry</i> , 2011, 286, 5956-5966.	3.4	58
65	Anti-interleukin 2 receptor monoclonal antibodies. Respective role of epitope mapping and monoclonal antibody-receptor interactions in their antagonist effects on interleukin 2-dependent T cell growth. <i>European Journal of Immunology</i> , 1986, 16, 611-616.	2.9	57
66	SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes. <i>Haematologica</i> , 2014, 99, 830-835.	3.5	55
67	Midostaurin in Advanced Systemic Mastocytosis. <i>New England Journal of Medicine</i> , 2016, 374, 2605-2606.	27.0	54
68	Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. <i>Blood</i> , 2010, 116, 1114-1123.	1.4	52
69	Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth. <i>Oncogene</i> , 2011, 30, 3862-3874.	5.9	52
70	Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice. <i>Cancer Cell</i> , 2005, 8, 467-478.	16.8	48
71	Novel, Soluble Isoform of the Herpes Simplex Virus (HSV) Receptor Nectin1 (or PRR1-HlgR-HveC) Modulates Positively and Negatively Susceptibility to HSV Infection. <i>Journal of Virology</i> , 2001, 75, 5684-5691.	3.4	46
72	Kit signaling inhibits the sphingomyelin-ceramide pathway through PLC β 1: implication in stem cell factor radioprotective effect. <i>Blood</i> , 2002, 100, 1294-1301.	1.4	46

#	ARTICLE	IF	CITATIONS
73	Mast cell sarcoma: new cases and literature review. <i>Oncotarget</i> , 2016, 7, 66299-66309.	1.8	46
74	Mast cell leukemia: identification of a new <i>c-Kit</i> mutation, dup(501â€502), and response to masitinib, a <i>c-Kit</i> tyrosine kinase inhibitor. <i>European Journal of Haematology</i> , 2012, 89, 47-52.	2.2	45
75	The tyrosine kinase FES is an essential effector of KITD816V proliferation signal. <i>Blood</i> , 2007, 110, 2593-2599.	1.4	44
76	Mast Cell Sarcoma: A Rare and Aggressive Entityâ€”Report of Two Cases and Review of the Literature. <i>Journal of Clinical Oncology</i> , 2013, 31, e90-e97.	1.6	43
77	Suppressor of Cytokine Signaling 1 Interacts with the Macrophage Colony-stimulating Factor Receptor and Negatively Regulates Its Proliferation Signal. <i>Journal of Biological Chemistry</i> , 2001, 276, 22133-22139.	3.4	42
78	Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2387-2395.e3.	3.8	42
79	Oncogenic Tyrosine Kinase of Malignant Hemopathy Targets the Centrosome. <i>Cancer Research</i> , 2005, 65, 7231-7240.	0.9	37
80	PICK-1: A scaffold protein that interacts with Nectins and JAMs at cell junctions. <i>FEBS Letters</i> , 2005, 579, 2243-2249.	2.8	35
81	Dual Role of the Tyrosine Kinase Syk in Regulation of Toll-Like Receptor Signaling in Plasmacytoid Dendritic Cells. <i>PLoS ONE</i> , 2016, 11, e0156063.	2.5	35
82	Screening of candidate G-quadruplex ligands for the human <i>c-KIT</i> promotorial region and their effects in multiple <i>in-vitro</i> models. <i>Oncotarget</i> , 2016, 7, 21658-21675.	1.8	35
83	Molecular Modeling of Wild-Type and D816V <i>c-Kit</i> Inhibition Based on ATP-Competitive Binding of Ellipticine Derivatives to Tyrosine Kinases. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 6194-6201.	6.4	34
84	Phosphatidylinositol-3â€ Kinase Is Not Required for Mitogenesis or Internalization of the Flt3/Flk2 Receptor Tyrosine Kinase. <i>Journal of Biological Chemistry</i> , 1996, 271, 20075-20081.	3.4	32
85	Masitinib demonstrates antiâ€proliferative and proâ€apoptotic activity in primary and metastatic feline injectionâ€site sarcoma cells [*] . <i>Veterinary and Comparative Oncology</i> , 2012, 10, 143-154.	1.8	32
86	The Mouse <i>W/c-kit</i> Locus.. <i>Annals of the New York Academy of Sciences</i> , 1990, 599, 58-65.	3.8	31
87	Chimeric Nectin1-Poliovirus Receptor Molecules Identify a Nectin1 Region Functional in Herpes Simplex Virus Entry. <i>Journal of Virology</i> , 2001, 75, 7987-7994.	3.4	31
88	The E3 ubiquitin ligase HOIL-1 induces the polyubiquitination and degradation of SOCS6 associated proteins. <i>FEBS Letters</i> , 2006, 580, 2609-2614.	2.8	31
89	AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells. <i>Leukemia</i> , 2007, 21, 877-885.	7.2	31
90	Trans-inhibition of activation and proliferation signals by Fc receptors in mast cells and basophils. <i>Science Signaling</i> , 2016, 9, ra126.	3.6	31

#	ARTICLE	IF	CITATIONS
91	Imatinib Mesylate in the Treatment of Diffuse Cutaneous Mastocytosis. <i>Journal of Pediatrics</i> , 2013, 162, 205-207.	1.8	30
92	Telangiectasia macularis eruptiva perstans (TMEP): A form of cutaneous mastocytosis with potential systemic involvement. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 885-891.e1.	1.2	30
93	Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. <i>British Journal of Haematology</i> , 2019, 187, 488-501.	2.5	30
94	FES kinases are required for oncogenic FLT3 signaling. <i>Leukemia</i> , 2010, 24, 721-728.	7.2	28
95	Transformation of LMTK ⁺ cells with purified HLA class I genes. <i>Immunogenetics</i> , 1983, 18, 65-77.	2.4	27
96	Response of a KIT-Positive Extra-Abdominal Fibromatosis to Imatinib Mesylate and KIT Genetic Analysis. <i>Journal of the National Cancer Institute</i> , 2006, 98, 562-563.	6.3	27
97	Hotspot Mutations in KIT Receptor Differentially Modulate Its Allosterically Coupled Conformational Dynamics: Impact on Activation and Drug Sensitivity. <i>PLoS Computational Biology</i> , 2014, 10, e1003749.	3.2	27
98	The MEK1/2-ERK Pathway Inhibits Type I IFN Production in Plasmacytoid Dendritic Cells. <i>Frontiers in Immunology</i> , 2018, 9, 364.	4.8	26
99	Effects of Chronic Masitinib Treatment in APP ^{swe} /PSEN1 ^{dE9} Transgenic Mice Modeling Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1339-1345.	2.6	26
100	Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma. <i>Journal of Clinical Investigation</i> , 2017, 127, 2310-2325.	8.2	26
101	Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate. <i>Oncogene</i> , 2007, 26, 3904-3908.	5.9	25
102	Blood CD34 ⁺ c-Kit ⁺ cell rate correlates with aggressive forms of systemic mastocytosis and behaves like a mast cell precursor. <i>Blood</i> , 2011, 118, 5246-5249.	1.4	25
103	Nectin-3 (CD113) Interacts with Nectin-2 (CD112) to Promote Lymphocyte Transendothelial Migration. <i>PLoS ONE</i> , 2013, 8, e77424.	2.5	25
104	Leukocyte telomere length in mastocytosis: Correlations with depression and perceived stress. <i>Brain, Behavior, and Immunity</i> , 2014, 35, 51-57.	4.1	25
105	Neuroprotective effect of masitinib in rats with postischemic stroke. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2015, 388, 79-86.	3.0	25
106	Masitinib as a chemosensitizer of canine tumor cell lines: A proof of concept study. <i>Veterinary Journal</i> , 2012, 191, 131-134.	1.7	23
107	KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570. <i>Oncogene</i> , 2014, 33, 872-881.	5.9	23
108	Kit signaling and negative regulation of daunorubicin-induced apoptosis: role of phospholipase C β 3. <i>Oncogene</i> , 2001, 20, 6752-6763.	5.9	21

#	ARTICLE	IF	CITATIONS
109	Adult T cell leukemia aggressiveness correlates with loss of both 5-hydroxymethylcytosine and TET2 expression. <i>Oncotarget</i> , 2017, 8, 52256-52268.	1.8	20
110	Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial. <i>Veterinary Dermatology</i> , 2011, 22, 554-564.	1.2	19
111	Molecular basis of mast cell disease. <i>Molecular Immunology</i> , 2015, 63, 55-60.	2.2	19
112	Tyrosine Kinase Inhibitors Induce Down-Regulation of c-Kit by Targeting the ATP Pocket. <i>PLoS ONE</i> , 2013, 8, e60961.	2.5	19
113	Comparison of Murine and Human Nectin1 Binding to Herpes Simplex Virus Glycoprotein D (gD) Reveals a Weak Interaction of Murine Nectin1 to gD and a gD-Dependent Pathway of Entry. <i>Virology</i> , 2001, 282, 256-266.	2.4	18
114	Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology. <i>Nature Communications</i> , 2017, 8, 1420.	12.8	18
115	Capture of cytokine-responsive genes (NACA and RBM3) using a gene trap approach. <i>Blood</i> , 2000, 95, 3750-3757.	1.4	17
116	NACA is a positive regulator of human erythroid-cell differentiation. <i>Journal of Cell Science</i> , 2005, 118, 1595-1605.	2.0	17
117	An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 7, 51163-51173.	1.8	15
118	KIT as a therapeutic target for non-oncological diseases. , 2019, 197, 11-37.		14
119	Efficacy and Safety of Cladribine in Adult Systemic Mastocytosis : A French Multicenter Study of 33 Patients.. <i>Blood</i> , 2004, 104, 661-661.	1.4	12
120	Long Term Efficacy and Safety of Cladribine In Adult Systemic mastocytosis: a French Multicenter Study of 44 Patients. <i>Blood</i> , 2010, 116, 1982-1982.	1.4	12
121	The Human Poliovirus Receptor Related 2 Protein Is a New Hematopoietic/Endothelial Homophilic Adhesion Molecule. <i>Blood</i> , 1998, 92, 4602-4611.	1.4	12
122	Recent advances in the understanding and therapeutic management of mastocytosis. <i>F1000Research</i> , 2019, 8, 1961.	1.6	12
123	Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors. <i>PLoS ONE</i> , 2015, 10, e0142450.	2.5	10
124	Criteria for the Regression of Pediatric Mastocytosis: A Long-Term Follow-Up. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1695-1704.e5.	3.8	10
125	Identification on I-Ak molecules of a functional site recognized by proliferating T-lymphocytes. <i>Immunogenetics</i> , 1982, 16, 407-424.	2.4	9
126	Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour. <i>Oncology Reports</i> , 2006, 16, 97.	2.6	9

#	ARTICLE	IF	CITATIONS
127	Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study. <i>British Journal of Haematology</i> , 2013, 161, 434-442.	2.5	9
128	Capture of cytokine-responsive genes (NACA and RBM3) using a gene trap approach. <i>Blood</i> , 2000, 95, 3750-3757.	1.4	9
129	Affinity and Inhibitory Capacity of T-Cell Proliferation of Monoclonal Anti-Ia Antibodies. <i>Scandinavian Journal of Immunology</i> , 1982, 16, 233-241.	2.7	8
130	Functional characterization of human CD34+ cells that express low or high levels of the membrane antigen CD111 (nectin 1). <i>Leukemia</i> , 2003, 17, 1137-1145.	7.2	8
131	Relocalization of KIT D816V to Cell Surface After Dasatinib Treatment: Potential Clinical Implications. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 62-69.	0.4	8
132	Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis. <i>Clinical and Experimental Allergy</i> , 2016, 46, 133-141.	2.9	8
133	Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2015, 159, 695-697.	0.6	8
134	Familial hematological malignancies: new IDH2 mutation. <i>Annals of Hematology</i> , 2016, 95, 1943-1947.	1.8	7
135	FES kinase participates in KIT-ligand induced chemotaxis. <i>Biochemical and Biophysical Research Communications</i> , 2010, 393, 174-178.	2.1	6
136	Characterization of S628N. <i>JAMA Dermatology</i> , 2014, 150, 1345.	4.1	6
137	Mastocytosis among elderly patients. <i>Medicine (United States)</i> , 2016, 95, e3901.	1.0	6
138	KLH-specific, I-E/C-restricted clones of proliferating T lymphocytes. <i>Immunogenetics</i> , 1981, 14, 469-479.	2.4	5
139	Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAILR) in mast cells. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 764-774.	5.7	5
140	The association of Greig syndrome and mastocytosis reveals the involvement of the hedgehog pathway in advanced mastocytosis. <i>Blood</i> , 2021, 138, 2396-2407.	1.4	5
141	Specific and common activities of the FLT3 and KIT tyrosine kinase receptors revealed by the use of cultured mast cells. <i>Leukemia</i> , 1998, 12, 1089-1098.	7.2	4
142	Decreased tryptophan and increased kynurenine levels in mastocytosis associated with digestive symptoms. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 416-420.	5.7	4
143	GlcNAc is a mast-cell chromatin-remodeling oncometabolite that promotes systemic mastocytosis aggressiveness. <i>Blood</i> , 2021, 138, 1590-1602.	1.4	4
144	Masitinib plus FOLFIRI for second line treatment of metastatic colorectal cancer: An open label phase Ib/II trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 3526-3526.	1.6	4

#	ARTICLE	IF	CITATIONS
145	TET2 regulates immune tolerance in chronically activated mast cells. JCI Insight, 2022, 7, .	5.0	4
146	Desmoid-Type Fibromatosis. Journal of Neurosurgery, 2007, 107, 473-475.	1.6	3
147	Absence of circulating mast cell precursors in paediatric mastocytosis: could it reflect a different pathophysiology between adults and children with mastocytosis?. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 967-971.	2.4	3
148	Treatment of Advanced Systemic Mastocytosis with PKC412: The French Compassionate Use Programme Experience and Historical Comparison. Blood, 2014, 124, 3193-3193.	1.4	3
149	Mouse monoclonal anti-Ia antibodies recognize cross-reacting determinants expressed on distinct subsets of human Ia-like cell-surface molecules†. Molecular Immunology, 1983, 20, 511-520.	2.2	2
150	Mast cell activation syndrome: High frequency of skin manifestations and anaphylactic shock. Allergology International, 2019, 68, 119-121.	3.3	2
151	Neuroinflammatory disorders and mastocytosis: A possible association?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2878-2881.e1.	3.8	2
152	Cell surface fixation of alloantigen bearing plasma vesicles in the presence of polyethylene glycol. Journal of Immunological Methods, 1981, 44, 285-299.	1.4	1
153	Human erythroleukemia: is the two-hit model of mouse leukemogenesis valid in human disease?. Leukemia, 2007, 21, 2212-2214.	7.2	1
154	Masitinib plus irinotecan for second line treatment of esophagogastric adenocarcinoma: An open label phase Ib/II trial.. Journal of Clinical Oncology, 2015, 33, 4027-4027.	1.6	1
155	F.115. Mastocytosis in Mice Expressing Human Kit Receptor with the Activating Asp816val Mutation. Clinical Immunology, 2006, 119, S91.	3.2	0
156	Recurrent TET2 mutations in adult T cell leukemia (ATL) and identification of a Single Nucleotide polymorphism in TET2 region predisposing to ATL development. Retrovirology, 2015, 12, .	2.0	0
157	Isolated flushes without permanent, fixed or other skin lesions in patients with systemic mastocytosis: a case series of 9 patients. European Journal of Dermatology, 2015, 25, 182-184.	0.6	0
158	«Le piége de gènes» : un outil efficace de la génomique fonctionnelle. Medecine/Sciences, 2002, 18, 667-670.	0.2	0
159	Masitinib plus carboplatin and gemcitabine for treatment of patients with advanced triple negative breast cancer: An open label phase Ib/II trial.. Journal of Clinical Oncology, 2015, 33, 1070-1070.	1.6	0
160	Development of Masitinib for the Treatment of Peripheral T-Cell Lymphoma. Blood, 2015, 126, 3993-3993.	1.4	0
161	Abstract 4868: Tyrosine kinase-dependent modulation of tumor infiltrating immune cells in melanoma. , 2016, , .		0